Advertisement

The Monocytic Component in Myelodysplastic Syndromes

  • Gianluigi Castoldi
  • Gian Matteo Rigolin
Part of the Cancer Treatment and Research book series (CTAR, volume 108)

Abstract

The involvement of the monocytic component in myelodysplastic syndromes (MDS) was confined for a long time mainly to the identification of a single disease, the Chronic Myelo-Monocytic Leukemia (CMML). However, more recently, the monocytes have been re-evaluated in other MDS as possible target cells directly participating into the clonal process. In MDS other than CMML, monocytes reflect the abnormality of the progenitor cells even though their contribution to the pathological aspects of the disease is sometimes not clearly expressed. Immunophenotypic and molecular studies have demonstrated that, in MDS, the malignant transformation occurs mainly at the level of the myeloid stem cells. In particular fluorescent in situ hybridization (FISH) analysis of progenitor cells sorted by FACS has shown that, in MDS patients with trisomy 8, only the stem cells at the CFU-GEMM level (CD34+/CD33+ cells) presented the +8 chromosome abnormality while the pluripotent stem cells (CD34+/Thyl+), the lymphoid B (CD34+/CD19+) and T (CD34+/CD7+) cells did not show the trisomy 8 (Saitoh et al., 1998). However, more recently, it has been demonstrated that, in 5q- MDS, the deletion occurrred in hemopoietic cells endowed with lympho-myeloid potential even though these CD34+CD38- cells were inefficient at reconstituting hemopoiesis in a NOD/SCID mouse model ([Nilsson et al., 2000]). Whatever the case, monocytes which directly derive from the CFUGEMM progenitor cells, are part of the malignant clone.

Keywords

Acute Myeloid Leukemia Myelodysplastic Syndrome Peripheral Blood Monocyte Myeloproliferative Disorder Chronic Myelomonocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, G., Gralnick, H. & Sultan C. (1982) Proposals for the classification of myelodysplastic syndromes.British Journal of Haematology51, 189–199.PubMedGoogle Scholar
  2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, G., Gralnick, H., Sultan C. & Cox, C. (1994) The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French-American-British cooperative leukemia group.British Journal of Haematology87, 746–754.PubMedCrossRefGoogle Scholar
  3. Castoldi, G. & Cuneo, A. (1996) Special cytological subtypes of acute myeloid leukemias and myelodysplastic syndromes.Baillière’s Clinical Haematology9, 19–33.PubMedCrossRefGoogle Scholar
  4. Clark, R.E., Hoy, T.G. & Jacobs, A. (1985) Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.Journal of Clinical Pathology38, 301–304.PubMedCrossRefGoogle Scholar
  5. De Greef, G. & Hagemeijer, A. (1996) Molecular and cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndromes.Baillière’s Clinical Haematology9, 1–18.PubMedCrossRefGoogle Scholar
  6. Elghetany, M.T. (1998) Surface marker abnormalities in myelodysplastic syndromes.Haematologica83, 1104–115.PubMedGoogle Scholar
  7. Felzmann, T., Gisslinger, H., Krieger, O., Majadic, O., Ludwig, H. & Koller, U. (1993) Imunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome.British Journal of Haematology84, 428–435.PubMedCrossRefGoogle Scholar
  8. Gallagher, A., Darley, R.L. & Padua, R.A. (1997) The molecular basis of myelodysplastic syndromes.Haematologica82, 191–204.PubMedGoogle Scholar
  9. Germing, U., Gatterman, N., Minning, H., Heyll, A. & Aul, C. (1998) Problems in the classification of CMML — dysplastic versus proliferative type.Leukemia Research22, 871–878.PubMedCrossRefGoogle Scholar
  10. Gersuk, G.M., Beckham, C., Laken, M.R., Kiener, P., Anderson, J.E., Farrand, A., Troutt, A.B., Ledbetter, J.A. & Decg, H.J. (1998) A role for tumour necrosis factor alpha, FAS and FAS-ligand in marrow failure associated with myelodysplastic syndromes.British Journal of Haematology103, 176–188.PubMedCrossRefGoogle Scholar
  11. Golub, T.R., Bvarker, G.F., Lovett, M., et al. (1994) Fusion of PDGF receptor beta a novel etslike gene, TEL, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.Cell77, 307–318.PubMedCrossRefGoogle Scholar
  12. Greenberg, P., Cox, C., Le Beau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood89, 2079–2088.PubMedGoogle Scholar
  13. Guyotat, D., Campos, L., Thomas, X., et al. (1990) Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns.Google Scholar
  14. Hamblin, T.J. (1992) Clinical features of MDS.Leukemia Research16, 89–93.PubMedCrossRefGoogle Scholar
  15. Hamblin, T.J. (1996) Immunological abnormalities in myelodysplastic syndromes.Seminars in Hematology33, 150–162.PubMedGoogle Scholar
  16. Harris, M.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health classification of neoplastic diseases of the hematopoitic and lymphoid tissues: report of the clinical advisory committee meeting — Airlie House, Virginia, November 1997.Journal of Clinical Oncology17, 3835–3849.PubMedGoogle Scholar
  17. Heim, S. & Mitelman, F. (1995) Cancer Cytogenetics. Second Edition John Wiley & Sons, Inc., New York.Google Scholar
  18. Hockland, P., Kendrup, G., Griffin, J.D. & Ellegaard, J. (1986) Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies.Blood67, 898–902.Google Scholar
  19. Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, M., Kamiyama, R. & Hirokawa, K. (1997) Overexpression of tumor necrosis factor (TNF)alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes.Leukemia 112049–2054.PubMedCrossRefGoogle Scholar
  20. Koike, M., Ishiyama, T., Tomoyasu, S. & Tsuruoka, N. (1995) Spontaneous cytokine overproduction by peripheral blood mononuclear cells from patients with myelodysplastic syndromes and aplastic anemia.Leukemia Research9, 639–644.CrossRefGoogle Scholar
  21. Kouides, P.A. & Bennett, J.M. (1996) Morphology and classification of the myelodysplastic syndromes and their pathologic variants.Seminars in Hematology33, 95–110.PubMedGoogle Scholar
  22. Kristensen, J.S. & Hockland, P. (1990) Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes.British Journal of Haematology74, 270–276.PubMedCrossRefGoogle Scholar
  23. Lanza, F., Castagnari, B., Rigolin, G., Latorraca, A., Ferrari, L., Bardi, A. & Castoldi, G. (1997) Flow cytometry measurement of GM-CSF receptors in acute leukemic blasts and normal hemopoietic cells.Leukemia 111700–1710.PubMedCrossRefGoogle Scholar
  24. Lyons, J., Janssen, J.W., Bartram, C., Layton, M. & Mufti G.J. (1988) Mutations of Ki-ras and N-ras oncogenes in myelodysplastic syndromes.Blood71, 1707–1712.PubMedGoogle Scholar
  25. Maciejewski, I., Selleri, C., Anderson, S. & Young, N.S. (1995) Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine mediated hematopoietic suppression in vitro.Blood85, 3183–3190.PubMedGoogle Scholar
  26. Mangi, M.H. & Mufti, G.J. (1992) Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.Blood79, 198–205.PubMedGoogle Scholar
  27. Nilsson, L., Astrand-Grunstrom, I., Arvidsson, I., Jacobsson, B., Hellstrom-Lindberg, E. Hast, & Jacobsen, S.E.W. (2000) Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for the involvement at he hematopoietic stem cell level.Blood96, 212–2021.Google Scholar
  28. Ohyashiki, K., Yokoyama, K., Kimura, Y., Ohyashiki, J.H., Ito, T., Kuratsuji, T., Komatsumoto, S., Nara, M. & Toyama, K. (1993) Myclodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?Leukemia7, 338–340.PubMedGoogle Scholar
  29. Oscier, D.G. (1996) Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome?British Journal of Haematology92, 582–586.PubMedCrossRefGoogle Scholar
  30. Oscier, D.G. & Chapman, R. (1998) The classification of chronic myelomonocytic leukemia.Leukemia Research22, 879–880.PubMedCrossRefGoogle Scholar
  31. Padua, R.A., Guinn, B.-A., Al-Sabah, A., Smoth, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. & West, R. (1998) RAS, FMS and P53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.Leukemia12, 887–892.PubMedCrossRefGoogle Scholar
  32. Parker, J.E. & Mufti, G.J. (1998) Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes.British Journal of Haematology 101220–230.PubMedCrossRefGoogle Scholar
  33. Pedersen-Bjergaard, J. & Rowley, J.D. (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation.Blood83, 2780–2786.PubMedGoogle Scholar
  34. Raza, A., Gezer, S., Mundle, S., Gao, X.-Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes.Blood86, 268276.Google Scholar
  35. Raza, A., Gawl, H., Lisak, L., Andric, T., Dar, S., Adrews, C., Venugopal, P., Gezer S., Gregory, S., Loew, J., Robin, E., Rifkin, S., Hsu, W.-T-. & Huang R.-W. (2000) Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.Blood95, 1580–1587.PubMedGoogle Scholar
  36. Rigolin, G.M., Cuneo, A., Roberti, M.G., Bardi, A. & Castoldi G. (1997) Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization.Haematologica82, 25–30.PubMedGoogle Scholar
  37. Rigolin, G.M., Cuneo, A., Roberti, M.G., Bardi, A., Bigoni, R., Piva, N., Minotto, C., Agostini, P., De Angeli, C., Del Senno, L., Spanedda, R. & Castoldi G.L. (1998) Exposure to myelotoxic agents and myelodysplasia: case-control study and con-elation with clinicobiologic findings.British Journal of Haematology103, 189–197.PubMedCrossRefGoogle Scholar
  38. Rigolin, G.M., Howard, J., Buggins, A., Sneddon, C., Castoldi, G., Hirst, W.J.R. & Mufti, G. (1999) Phenotypic and functional characteristics of monocyte-derived dendritic cells from patients with myelodysplastic syndromes.British Journal of Haematology107, 844–850.CrossRefGoogle Scholar
  39. Rosenfeld, C. & List, A. (2000) A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.Leukemia14, 2–8.PubMedCrossRefGoogle Scholar
  40. Ross, T., Bernard, O.A., Berger, R. & Guillard, G.D. (1998) Fusion of Huntingtin interacting protein 1 to platelet derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia wih t(5;7)(g22:g11.2).Blood91, 4419–4426.PubMedGoogle Scholar
  41. Saitoh, K., Miura, I., Takahashi, N. & Miura A.B. (1998) Fluorescent in situ hybridisation of progenitor cells obtained by fluorescent-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.Blood92, 2886–2892.PubMedGoogle Scholar
  42. Sato, Y., Suto, Y., Pietenpol, J., et al. (1995) TEL and KIP1 define the smallest region on 12p13 in hematopoietic malignancies.Blood86, 1525–1533.PubMedGoogle Scholar
  43. Tobal, K., Pagliuca, A., Bhatt, B., Bailey, N., Layton, M. & Mufti, G.J. (1990) Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.Leukemia4, 486–489.PubMedGoogle Scholar
  44. Tricot, G., De Wolf-Peeters, C., Hendrickx, B. & Verwlghen, R.L. (1984) I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.British Journal of Haematology57, 423–430.PubMedCrossRefGoogle Scholar
  45. Vandenberghe, E., Baens, M., Stul, M., et al. (1991) Alterations of N-ras mutations in a patients with AML M4 and trilineage myelodysplasia.British Journal of Haematology79, 338–340.Google Scholar
  46. Verhoef, G.E.G., Demuynk, H., Zachee, P. & Boogaerts, M.A. (1994) Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two.Leukemia8, 714–715.PubMedGoogle Scholar
  47. Vuckovic, S., Feamley, D.B., Gunningham, S., Spearing, R.L., Patton, W.N. & Hart, D.N.J. (1999) Dendritic cells in chronic myelomonocytic leukemia.British Journal of Haematology105, 974–985.PubMedCrossRefGoogle Scholar
  48. Wessels, J.W., Fibbe, W.E., Van Der Keur, D., et al. (1993) t(5;12)(g31;p12). A clinical entity with features of both myeloid and chronic myelomonocytic leukemia.Cancer Genetics and Cytogenetics65, 7–15.PubMedCrossRefGoogle Scholar
  49. Wlodarska, J., Mecucci, C., Marynen, P., et al. (1995) TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(g33;p13) translocation or its variant t(10;12)(g24;p 13).Blood85, 2848–2852.PubMedGoogle Scholar
  50. Yunis, J.J., Boot, A.J., Mayer, M.G. & Bos, J.L. (1989) Mechanisms of ras mutations in myelodysplastic syndrome.Oncogene4, 609–614.PubMedGoogle Scholar
  51. Zanke, B., Squire, J., Griesser, H., et al. (1994) A hemopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1832.1.Leukemia8, 236–244.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Gianluigi Castoldi
    • 1
  • Gian Matteo Rigolin
    • 1
  1. 1.Hematology SectionUniversity of FerraraItaly

Personalised recommendations